Don't quite understand this: "interim analysis is expected when 50% of events (32 deaths) have been observed"
How do they arrive at the number of 32? I assume that is %50 of the patients using the product, not including placebo patients...At 115 patients 2:1 would be 38 placebo patients and 77 treated patients. hmmmmm, the numbers are still off.
I was just reading the FDA's trial site for the details and it said "OS defined as the time from randomization until date of death..." So the statistical number for randomization may be less than the 115 enrollment figure announced. The way I look at it is that the longer it takes for interim results than the higher the efficacy number will be. I'm an optimist!